NCT07217496View on ClinicalTrials.gov

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

May 30, 2027

Study Completion Date

May 30, 2027

Conditions
Metastatic Urothelial CarcinomaUrothelial CarcinomaLocally Advanced Urothelial CarcinomaUrothelial Cancer
Interventions
DRUG

Nogapendekin Alfa Inbakicept (N803)

Given subcutaneously (SC)

DRUG

Enfortumab Vedotin (EV)

Given intravenously (IV)

DRUG

Pembrolizumab

Given intravenously (IV)

PROCEDURE

Research Biospecimen Collection

Undergo blood collection for research purposes

PROCEDURE

Radiographic Imaging

Undergo radiographic imaging for disease assessment

PROCEDURE

Tumor Biopsy

Undergo tumor biopsy

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

ImmunityBio, Inc.
All Listed Sponsors
collaborator

ImmunityBio, Inc.

INDUSTRY

lead

Vadim S Koshkin

OTHER